Co-Occurrence of EBV-Positive Mucocutaneous Ulcer (EBV-MCU) and CLL/SLL in the Head and Neck Region.

Patricia Bott, Ilske Oschlies, Andreas Radeloff, Maureen Loewenthal

Open access · goldAbstract readCase ReportsReview

In one paragraph

Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.6field-weighted citation impact, top 31% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

Multifocal Epstein-Barr Virus-Positive Mucocutaneous Ulcers in a Patient With Crohn's Disease.ACG case reports journal · 2024
Article
Epstein-Barr Virus-Positive Mucocutaneous Ulcer on the Gingiva of a Patient in Whom Immunosuppressive Drugs Could Not Be Withdrawn: A Case Report and Review of the Literature.Cureus · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Patricia BottDivision of Otorhinolaryngology, Head and Neck Surgery, University of Oldenburg, Steinweg 13-17, 26122 Oldenburg, Germany.

Ilske OschliesHematopathology Section and Lymphnode Registry, Department of Pathology, University Hospitals Schleswig-Holstein, Christian-Albrecht-University, Arnold-Heller-Str. 3/14, 24105 Kiel, Germany.

Andreas RadeloffDivision of Otorhinolaryngology, Head and Neck Surgery, University of Oldenburg, Steinweg 13-17, 26122 Oldenburg, Germany.ORCID 0000-0003-1881-4179

Maureen LoewenthalDivision of Otorhinolaryngology, Head and Neck Surgery, University of Oldenburg, Steinweg 13-17, 26122 Oldenburg, Germany.

Carl von Ossietzky Universität Oldenburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EBV-positive mucocutaneous ulcer (EBV-MCU) was classified as a rare new entity of the lymphoproliferative B-cell diseases by the WHO in 2017 and must be distinguished from head and neck squamous cell carcinoma by early biopsy. The aim of the study is to raise awareness of the disease and to give a review of the current literature and a recommendation for EBV-MCU management. All EBV-MCU cases of the head and neck region published so far were included. We also report a case of a pharyngeal EBV-MCU in an 89-year-old patient who was immunosuppressed by chronic lymphatic leukaemia/small lymphocytic lymphoma (CLL/SLL). In contrast to all previously described cases, histopathology showed a co-infiltration of EBV-MCU and CLL/SLL. A total of 181 cases were identified on PubMed and summarised. EBV-MCU was predominantly caused by immunosuppressive drug therapy. Complete remission could be achieved in 68% of cases and was mainly attributed to a reduction of the immunosuppressive therapy alone (72%). However, some severe cases require more aggressive treatment. Regarding the various histopathologic similarities to other lymphoproliferative disorders, the diagnosis of EBV-MCU can be misleading, with a great impact on patient care and treatment. This diagnosis must be made with caution and requires a combination of clinical, morphological and immunophenotypic features.

Indexed as

Epstein-Barr Virus InfectionsLeukemia, Lymphocytic, Chronic, B-CellLymphoproliferative DisordersAged, 80 and overHerpesvirus 4, HumanHumansUlcerEBV-positive mucocutaneous ulcerEpstein–Barr virushead and neck ulcermucocutaneous ulcer

Identifiers

PMID35448198

DOI10.3390/curroncol29040224

PMCPMC9026795

OpenAlexW4223929316

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.